For how we live.
In 273,466 people with substance-related hospital admissions, psychosis was far more common after hallucinogen admissions, until adjustment for preexisting conditions erased the link.
A cross-sectional analysis of NICE evaluations found 78 supporting studies behind 30 technologies — and consistent holes in comparators, cost of delivery and adverse-event reporting.
Bristol Myers Squibb found 'irregularities' in how a small number of ADEPT-2 sites executed the study, excluded their patients, and is enrolling more. Alzheimer's-related psychosis still has no approved treatment.